Physician profile
Umangi Ashvin Patel
NPI 1780259101
$2,726.24
in general payments reported to CMS, 2019-2025
8 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $570 · 2023: $383 · 2024: $846 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $793.87 | 2022-2025 | Hydrus Microstent, Clareon |
| Glaukos Corporation | $627.36 | 2022-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite, Idosetr |
| New World Medical,INC. | $557.28 | 2024-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Sight Sciences, INC. | $346.41 | 2021-2025 | Omni Surgical System |
| Genentech, INC. | $220.49 | 2023-2024 | Vabysmo |
| Dompe US, INC. | $120.32 | 2023 | Oxervate |
| Ivantis, INC | $43.17 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $17.34 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umangi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.